Addition to “Bioengineered Smart Nanocarriers for Breast Cancer Treatment: Adorned Carbon-Based Nanocomposites with Silver and Palladium Complexes for Efficient Drug Delivery”

ACS Omega 2024, 9 (1), 1183−1195. DOI: 10.1021/acsomega.3c07432. The authors wish to provide additional clarification regarding the palladium and silver complexes used in the study. In the published article, definitive molecular structures were not proposed for the palladium and silver complexes. The ¹H NMR spectra exhibit additional signals, consistent with the presence of multiple solution-phase species. These peaks are attributable to inadvertent impurities arising from trace water/moisture and remnants of reagents/solvents associated with the commercial reagents, original synthesis, and handling. Such phenomena are well-documented in the literature for the utilization of commercial palladium acetate as a precursor and the use of ammonia in the synthesis procedure. (1−6) All metal precursors (palladium acetate and silver chloride) were commercial materials used as received. The reported yields refer to the crude materials; no additional purification was performed prior to use. The as-prepared (crude) complexes were employed in all nanocarrier loading and release studies. Readers should interpret the biological assay results with the understanding that minor solution-phase species may be present in these materials (as additional purification was not performed). While these impurities may have a minor impact on the assays, they do not alter the study’s primary conclusions. This clarification does not alter the procedures reported or the qualitative interpretation that doxorubicin can be loaded onto and released from the carbon-based nanocarriers under the tested conditions. Textual correction: The correct reagent in the ligand synthesis is triphenylphosph a te (OP(OC₆H₅)₃), 20 mmol, 6.52 g (not triphenylphosphite).